Indication of major added benefit for Xtandi in over 75-year-olds, say IQWiG

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in a dossier assessment whether Xtandi (enzalutamide), from Medivation (Nasdaq: MDVN) and Japanese drug major Astellas Pharma (TYO: 4503), offers an added benefit over the appropriate comparator therapy for men who have metastatic prostate cancer.

According to the findings, in comparison with watchful waiting the drug can prolong overall survival and delay the occurrence of disease complications. In men aged 75 years or older, the IQWiG sees an indication of a major added benefit. There is also an indication of an added benefit in younger men; however, the extent is rated as “considerable”.

Approval study terminated prematurely